<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013320</url>
  </required_header>
  <id_info>
    <org_study_id>DEXLYCO</org_study_id>
    <nct_id>NCT05013320</nct_id>
  </id_info>
  <brief_title>Combined Dexmedetomidine and Glycopyrrolate Therapy</brief_title>
  <official_title>Combined Dexmedetomidine and Glycopyrrolate Therapy for Prevention of Catheter Related Bladder Discomfort After Transurethral Bladder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kangbuk Samsung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter-related bladder discomfort after transurethral resection of bladder tumor is&#xD;
      frequent because of indwelling urinary catheter for irrigation. The mechanism of the&#xD;
      catheter-related bladder discomfort is similar to that of overactive bladder, in which&#xD;
      muscarinic acetylcholine receptors are stimulated. The catheter-related bladder discomfort is&#xD;
      a well known predisposing factor for emergence delirium after general anesthesia. In this&#xD;
      study, we aimed to compare the incidence of catheter-related bladder discomfort between&#xD;
      dexmedetomidine only therapy and combind dexmedetomidine and glycopyrrolate therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We could not get the IRB approval&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of catheter-related bladder discomfort</measure>
    <time_frame>0 minute after entering the post-anesthetic care unit</time_frame>
    <description>No = not complaining of bladder discomfort on asking; Mild = report discomfot only on questioning; Moderate: report without questioning without behavior responses; Severe = report without questioniing accompanied by behavior responses. Mild, Moderate, Severe bladder discomfort is defined to have catheter-related bladder discomfort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergence agitation</measure>
    <time_frame>0 minute, 30 minute, and 6 hours after entering the post-anesthetic care unit</time_frame>
    <description>(1)calm (2)slightly agitated but consolable (3)moderately agitated and inconsolable (4)severely agitated and highly inconsolable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delirium</measure>
    <time_frame>0 minute, 30 minute, and 6 hours after entering the post-anesthetic care unit</time_frame>
    <description>(1)acute and fluctuating changes in mental status (2)inattention (3)disorganized or incoherent thinking (4)altered level of consciousness. (1),(2) and (3), (1),(2), and (4), or (1)(2)(3)and (4) are defined to have deilrium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>0 minute, 30 minute, and 6 hours after entering the post-anesthetic care unit</time_frame>
    <description>numerical rating scale (0=no pain to 10=worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation score</measure>
    <time_frame>0 minute, 30 minute, and 6 hours after entering the post-anesthetic care unit</time_frame>
    <description>(1)anxious, agitated or restless (2)cooperative, oriented and trranquil (3)responds to commands, asleep (4)brisk response to light glabellar taps or oud noise (5)sluggish response to light glabellar taps or loud noise (6)noresponse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry mouth</measure>
    <time_frame>0 minute, 30 minute, and 6 hours after entering the post-anesthetic care unit</time_frame>
    <description>yes or no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting</measure>
    <time_frame>0 minute, 30 minute, and 6 hours after entering the post-anesthetic care unit</time_frame>
    <description>yes or no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Bladder Irritable</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dexmedetomidine is administered during the surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined dexmedetomidine and glycopyrrolate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glycopyrrolate and dexmedetomidine are administered during the surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate + dexmedetomidine</intervention_name>
    <description>Intravenous glycopyrrolate before anesthetic induction. Dexmedetomidine administration during the surgery.</description>
    <arm_group_label>Combined dexmedetomidine and glycopyrrolate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine administration during the surgery.</description>
    <arm_group_label>Dexmedetomidine only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status I and II&#xD;
&#xD;
          -  elective transurethral resection of bladder tumor under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  arrhythmia&#xD;
&#xD;
          -  bladder outflow obstruction&#xD;
&#xD;
          -  overacitve bladder&#xD;
&#xD;
          -  end stage renal disease&#xD;
&#xD;
          -  neurogenic bladder&#xD;
&#xD;
          -  morbid obesity&#xD;
&#xD;
          -  psychiatric disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 13, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangbuk Samsung Hospital</investigator_affiliation>
    <investigator_full_name>Eunah Cho, MD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

